NCT01972737View on ClinicalTrials.gov

Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 3, 2014

Study Completion Date

January 13, 2016

Conditions
Colon Cancer
Interventions
BIOLOGICAL

Ad5-hGCC-PADRE vaccine

A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT01972737 - Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer | Biotech Hunter | Biotech Hunter